Wyeth Pharmaceuticals Spurring Scientific Creativity With Metrics Case Study

1. Johnson A. Insulin flop costs Pfizer $2.8 billion. 2007. http://www.wsj.com/articles/SB119269071993163273. Accessed 17 August 2016.

2. Gutierrez C. Pfizer washes its hands of Exubera. 2007. http://www.forbes.com/2007/10/18/pfizer-earnings-closer-markets-equities-cx_cg_1018markets47.html. Accessed 17 August 2016.

3. Rao A, Purkayastha D. “Exubera fiasco: what went wrong?”, teaching note 508-115-8. Hyderabad: ICMR Center for Management Research; 2008.

4. National Institute for Health and Care Excellence. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. 2013. https://www.nice.org.uk/guidance/ta284?unlid=5013752442016211165322. Accessed 17 August 2016.

5. National Institute for Health and Care Excellence. NICE issues final guidance aflibercept for colorectal cancer. 2014. https://www.nice.org.uk/news/press-and-media/nice-issues-final-guidance-aflibercept-for-colorectal-cancer. Accessed 17 August 2016.

6. Harrison RK. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov. 2016;15(12):817–818. doi: 10.1038/nrd.2016.184.[PubMed][Cross Ref]

7. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33. doi: 10.1016/j.jhealeco.2016.01.012.[PubMed][Cross Ref]

8. Griffin A, Hauser JR. Patterns of communication among marketing, engineering and manufacturing—a comparison between two new product teams. Manag Sci. 1992;38(3):360–373. doi: 10.1287/mnsc.38.3.360.[Cross Ref]

9. Olson EM, Walker OC, Jr, Ruekert RW, Bonner JM. Patterns of cooperation during new product development among marketing, operations and R&D: implications for project performance. J Prod Innov Manag. 2001;18(4):258–271. doi: 10.1016/S0737-6782(01)00091-1.[Cross Ref]

10. Slater SF, Mohr JJ, Sengupta S. Radical product innovation capability: literature review, synthesis, and illustrative research propositions. J Prod Innov Manag. 2014;31(3):552–566. doi: 10.1111/jpim.12113.[Cross Ref]

11. Calantone RJ, Schmidt JB, Di Benedetto CA. New product activities and performance: the moderating role of environmental hostility. J Prod Innov Manag. 1997;14(3):179–189. doi: 10.1111/1540-5885.1430179.[Cross Ref]

12. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–277. doi: 10.1038/clpt.2009.295.[PubMed][Cross Ref]

13. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959–968. doi: 10.1038/nrd2961.[PubMed][Cross Ref]

14. Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17(9/10):419–424. doi: 10.1016/j.drudis.2011.12.020.[PubMed][Cross Ref]

15. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–431. doi: 10.1038/nrd4309.[PubMed][Cross Ref]

16. Pharmaceutical Research and Manufacturers of America (PhRMA). Biopharmaceutical research & development: the process behind new medicines. 2015. http://www.phrma.org/report/biopharmaceutical-research-and-development-the-process-behind-new-medicines. Accessed 16 Sept 2016.

17. Hauser JR, Simester DI, Wernerfelt B. Internal customers and internal suppliers. J Mark Res. 1996;33(3):268–280. doi: 10.2307/3152124.[Cross Ref]

18. Souder WE. Achieving organizational consensus with respect to R&D project selection criteria. Manag Sci. 1975;21(6):669–681. doi: 10.1287/mnsc.21.6.669.[Cross Ref]

19. Dougherty D. Interpretive barriers to successful product innovation in large firms. Organ Sci. 1992;3(2):179–202. doi: 10.1287/orsc.3.2.179.[Cross Ref]

20. Cooper RG. Third-generation new product processes. J Prod Innov Manag. 1994;11(1):3–14. doi: 10.1016/0737-6782(94)90115-5.[Cross Ref]

21. Sharpe P, Keelin T. How SmithKline Beecham makes better resource-allocation decisions. Harv Bus Rev. 1997;76(2):45–46.[PubMed]

22. Cooper RG. Winning at new products: accelerating the process from idea to launch. Cambridge: Addison-Wesley; 2001.

23. Royer I. Why bad projects are so hard to kill. Harv Bus Rev. 2003;81(2):48–56.[PubMed]

24. Staw BM. Knee-deep in the big muddy: a study of escalating commitment to a chosen course of action. Organ Behav Hum Perform. 1976;16:27–44. doi: 10.1016/0030-5073(76)90005-2.[Cross Ref]

25. Bazerman MH, Beekun RI, Schoorman FD. Performance evaluation in a dynamic context: a laboratory study of the impact of a prior commitment to the rate. J Appl Psychol. 1982;67(6):873–876. doi: 10.1037/0021-9010.67.6.873.[Cross Ref]

26. Bazerman MH, Giuliano T, Appelman A. Escalation of commitment in individual and group decision making. Organ Behav Hum Perform. 1984;33(2):141–152. doi: 10.1016/0030-5073(84)90017-5.[Cross Ref]

27. Jonas E, Schulz-Hardt S, Frey D, Thelen N. Confirmation bias in sequential information search after preliminary decisions: an expansion of dissonance theoretical research on selective exposure to information. J Pers Soc Psychol. 2001;80(4):557–571. doi: 10.1037/0022-3514.80.4.557.[PubMed][Cross Ref]

28. Bolton LE. Stickier priors: the effects of nonanalytic versus analytic thinking in new product forecasting. J Mark Res. 2003;40(1):65–79. doi: 10.1509/jmkr.[Cross Ref]

29. Biyalogorsky E, Boulding W, Staelin R. Stuck in the past: why managers persist with new product failures. J Mark. 2006;70:108–121. doi: 10.1509/jmkg.70.2.108.[Cross Ref]

30. Russo JE, Schoemaker PJH. Managing overconfidence. Sloan Manag Rev. 1992;33(2):7–17.

31. Janis IL. Groupthink: psychological studies of policy decisions and fiascoes. Boston: Houghton Mifflin; 1982.

32. Hansen MT, Mors ML, Løvås B. Knowledge sharing in organizations: multiple networks, multiple phases. Acad Manag J. 2005;48(5):776–793. doi: 10.5465/AMJ.2005.18803922.[Cross Ref]

33. Hansen MT, Løvås B. How do multinational companies leverage technological competencies? Moving from single to interdependent explanations. Strateg Manag J. 2004;25(8/9):801–822. doi: 10.1002/smj.413.[Cross Ref]

34. Casciaro T, Lobo MS. Competent jerks, lovable fools, and the formation of social networks. Harv Bus Rev. 2005;83(6):92–99.[PubMed]

35. Zander U, Kogut B. Knowledge and the speed of the transfer and imitation of organizational capabilities: an empirical test. Organ Sci. 1995;6(1):76–92. doi: 10.1287/orsc.6.1.76.[Cross Ref]

36. Szulanski G. Exploring internal stickiness: impediments to the transfer of best practice within the firm. Strateg Manag J. 1996;17(S2):27–43. doi: 10.1002/smj.4250171105.[Cross Ref]

37. Azoulay P, Zivin JSG, Manso G. Incentives and creativity: evidence from the academic life sciences. RAND J Econ. 2011;42(3):527–554. doi: 10.1111/j.1756-2171.2011.00140.x.[Cross Ref]

38. Ederer F, Manso G. Is pay for performance detrimental to innovation? Manag Sci. 2013;59(7):1496–1513. doi: 10.1287/mnsc.1120.1683.[Cross Ref]

39. Tian X, Wang TY. Tolerance for failure and corporate innovation. Rev Financ Stud. 2014;27(1):211–255. doi: 10.1093/rfs/hhr130.[Cross Ref]

40. Loch CH, Tapper UAS. Implementing a strategy-driven performance measurement system for an applied research group. J Prod Innov Manag. 2002;19(3):185–198. doi: 10.1111/1540-5885.1930185.[Cross Ref]

41. Terwiesch C, Ulrich K. Managing the opportunity portfolio. Res Technol Manag. 2008;51(5):27–38.

42. Loch C, Kavadias S. Implementing strategy through projects. In: Morris PWG, Pinto J, Söderlund J, editors. The Oxford handbook of project management. Oxford: Oxford University Press; 2011. pp. 224–251.

43. Birkinshaw J. Strategies for managing internal competition. Calif Manag Rev. 2001;44(1):21–38. doi: 10.2307/41166109.[Cross Ref]

44. Schlapp J, Oraiopoulos N, Mak V. Resource allocation decisions under imperfect evaluation and organizational dynamics. Manag Sci. 2015;61(9):2139–2159. doi: 10.1287/mnsc.2014.2083.[Cross Ref]

45. Huckman RS, Pisano GP, Rennella M. Wyeth pharmaceuticals: spurring scientific creativity with metrics. Harvard Business School Case 607-008. 2010.

46. Lovallo D, Kahneman D. Delusions of success: how optimism undermines executives’ decisions. Harv Bus Rev. 2003;81(7):56–63.[PubMed]

47. Hammond JS, Keeney RL, Raiffa H. The hidden traps in decision making. Harv Bus Rev. 1998;76(5):47–58.[PubMed]

48. Sengupta K, Abdel-Hamid TK, Van Wassenhove LN. The experience trap. Harv Bus Rev. 2008;86(2):94–101.[PubMed]

49. European Medicines Agency. “Best practice guidance for the parallel regulatory—HTA scientific advice procedure”. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500203944.pdf. Accessed 17 August 2016.

50. Christensen C, Hall T, Dillon K, Duncan D. Know your customers’ “jobs to be done” Harv Bus Rev. 2016;94(9):54–62.

51. Sullivan W, Hirst M, Beard S, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ. 2016;17(6):755–770. doi: 10.1007/s10198-015-0720-y.[PMC free article][PubMed][Cross Ref]

52. Hansen MT. Collaboration: how leaders avoid the traps, create unity, and reap big results. Boston: Harvard Business Press; 2009.

53. Dunlop WCN, Mullins CD, Pirk O, et al. BEACON: a summary framework to overcome potential reimbursement hurdles. PharmacoEconomics. 2016[PMC free article][PubMed]

54. Hansen MT, von Oetinger B. Introducing T-shaped managers: knowledge management’s next generation. Harv Bus Rev. 2001;79(3):106–116.[PubMed]

55. Hansen MT, Nohria N, Tierney T. What’s your strategy for managing knowledge? Harv Bus Rev. 1999;77(2):106–116.[PubMed]

56. Troy LC, Hirunyawipada T, Paswan AK. Cross-functional integration and new product success: an empirical investigation of the findings. J Mark. 2008;72(6):132–146. doi: 10.1509/jmkg.72.6.132.[Cross Ref]

57. Kim WC, Mauborgne R. Fair process: managing in the knowledge economy. Harv Bus Rev. 2003;81(1):127–136.

На своем Скайпейджере он установил режим вибрации без звонка, значит, кто-то прислал коммандеру сообщение. Шестью этажами ниже Стратмор стоял возле рубильника. В служебных помещениях ТРАНСТЕКСТА было черно как глубокой ночью. Минуту он наслаждался полной темнотой.


Leave a Reply

Your email address will not be published. Required fields are marked *